Recombinant Human PLAU Protein, N-His

Introduction to Recombinant Human PLAU Protein

Recombinant human PLAU protein, also known as urokinase-type plasminogen activator (uPA), is a type of recombinant protein that plays a crucial role in the regulation of the fibrinolytic system. It is a serine protease that is responsible for the conversion of plasminogen to plasmin, a key enzyme involved in the breakdown of blood clots. This protein has been widely studied and has been found to have a diverse range of functions in various physiological and pathological processes.

Structure of Recombinant Human PLAU Protein

Recombinant human PLAU protein is a glycosylated protein with a molecular weight of approximately 54 kDa. It is composed of 431 amino acids and has a primary structure similar to that of the natural human protein. The protein has a three-domain structure, consisting of a growth factor-like domain, a kringle domain, and a serine protease domain. The growth factor-like domain is responsible for binding to its receptor, while the kringle domain is involved in regulating its activity. The serine protease domain contains the active site of the protein and is responsible for its enzymatic function.

Activity of Recombinant Human PLAU Protein

The primary function of recombinant human PLAU protein is the conversion of plasminogen to plasmin. Plasmin plays a crucial role in the degradation of fibrin, the main component of blood clots. This activity is essential in maintaining the balance between clot formation and dissolution, preventing the formation of excessive blood clots. In addition to its role in the fibrinolytic system, recombinant human PLAU protein also has other activities, such as promoting cell migration and invasion, regulating cell proliferation and differentiation, and modulating the immune response.

Application of Recombinant Human PLAU Protein

Recombinant human PLAU protein has a wide range of applications in both research and clinical settings. One of its main uses is in the treatment of thrombotic disorders, such as deep vein thrombosis and pulmonary embolism. The protein is also used in the management of acute ischemic stroke, where it is administered intravenously to dissolve blood clots and restore blood flow to the brain. In addition, recombinant human PLAU protein has potential applications in cancer therapy. Its ability to promote cell migration and invasion makes it a potential target for the treatment of metastatic cancers. Furthermore, the protein has been found to have anti-inflammatory properties, making it a potential therapeutic agent for inflammatory diseases.

Recombinant Human PLAU Protein as an Antigen

Recombinant human PLAU protein has also been used as an antigen in various diagnostic and research applications. Antibodies against this protein have been developed and used for the detection of PLAU levels in biological samples, such as blood and tissue. These antibodies have also been used in immunohistochemistry to study the expression and localization of PLAU in different tissues. In addition, recombinant human PLAU protein has been used as an antigen in vaccine development, as it can induce an immune response against the protein, potentially providing protection against certain diseases.

Conclusion

In conclusion, recombinant human PLAU protein is a crucial protein involved in the regulation of the fibrinolytic system. Its structure, activity, and diverse range of applications make it a valuable tool in both research and clinical settings. With ongoing research and advancements in technology, the potential uses of recombinant human PLAU protein continue to expand, making it an important protein in the field of biotechnology and medicine.